United States Patent 12,419,895: Scope, Claim Architecture, and Competitive Landscape for Diazoxide Choline in Prader-Willi Syndrome Hyperphagia
What is the patented method and what does it require?
US Patent 12,419,895 claims a use-method for treating hyperphagia and at least one food-related behavior in a subject diagnosed with Prader-Willi Syndrome (PWS). The method is defined by a rigid combination of (i) patient population, (ii) dosing frequency, (iii) drug identity, (iv) dosing amount ranges, and (v) a clinical outcome.
Core method (Claim 1)
Claim 1 requires all of the following:
- Patient: “a subject having Prader-Willi Syndrome (PWS)”
- Condition/endpoint: “treating hyperphagia” and reducing “one or more food related behaviors”
- Drug identity: “a pharmaceutical formulation comprising an effective amount of diazoxide choline”
- Dosing cadence: “administering once per day”
- Effect: “administration reduces hyperphagia and one or more food related behaviors”
This is not a composition patent. It is a method-of-treatment claim that is likely infringed by clinical treatment and labeling-consistent prescribing if the claimed conditions are met.
How do the dependent claims narrow the scope?
The dependent claims add constraints in five buckets: duration, dose amount bands, titration schema, and route.
Duration limitations (Claims 2-3)
- Claim 2: diazoxide choline administered for at least 10 weeks
- Claim 3: diazoxide choline administered for one or more years
Practical effect: These claims create two temporal fences: a shorter “signal durability” fence (10+ weeks) and a longer “chronic management” fence (1+ year). In litigation, duration can be determinative if accused dosing is intermittent or if real-world treatment does not reach the stated timelines.
Dose bands for once-daily administration (Claims 4-15)
Claim 4 and Claims 5-9 create multiple overlapping quantitative ranges for once-daily dosing “in an amount from” X to Y mg. The claim set repeats dose bands again for the longer-duration claim set in Claims 10-15.
Once-daily dose ranges (Claims 4-9):
- 25 mg to 100 mg (Claim 4)
- 50 mg to 180 mg (Claim 5)
- 50 mg to 275 mg (Claim 6)
- 300 mg to 500 mg (Claim 7)
- 500 mg to 2000 mg (Claim 8)
- 25 mg to 500 mg (Claim 9)
Once-daily dose ranges tied to “one or more years” (Claims 10-15):
- 25 mg to 100 mg (Claim 10)
- 50 mg to 180 mg (Claim 11)
- 50 mg to 275 mg (Claim 12)
- 300 mg to 500 mg (Claim 13)
- 500 mg to 2000 mg (Claim 14)
- 25 mg to 500 mg (Claim 15)
Practical effect: This is an unusually granular dosing matrix. Even though ranges overlap, each dependent claim can be asserted if the accused regimen falls within its specific bracket. The existence of both narrow and broad ranges reduces “design-around” by dosing selection.
Titration method (Claims 16-25)
These claims specify how dosing ramps to maintenance, locking in a cadence and titration interval.
- Claim 16: initiated at a starting dose, then titrated every two weeks to reach a maintenance dose
- Claim 17: starting dose 25-100 mg
- Claim 18: starting dose 50-180 mg
- Claim 19: maintenance 100-200 mg
- Claim 20: maintenance 200-300 mg
- Claim 21: maintenance 300-500 mg
- Claim 22: maintenance 500-2000 mg
- Claim 23: maintenance 100-500 mg
- Claim 24: maintenance 25-250 mg
- Claim 25: maintenance 200-300 mg
Practical effect: Claims 16-25 can be asserted against any regimen that matches both the two-week titration interval and the starting-to-maintenance dose geometry. This limits defenses based on different titration timing or titration to a non-matching maintenance range.
Route (Claim 26)
- Claim 26: formulation is administered orally
Practical effect: Oral dosing is explicitly claimed. If an accused product is administered via another route (e.g., parenteral), Claim 26 would not be met. However, oral administration is the likely commercial default for this type of therapy, and it may preserve broad infringement risk for many treatment settings.
What is the claim “scope map” across time, dose, and titration?
Scope dimensions
- Population: PWS
- Indication/endpoint: hyperphagia + at least one food-related behavior reduction
- Drug: diazoxide choline
- Frequency: once daily
- Time: at least 10 weeks, and/or 1+ year
- Dose: multiple mg bands
- Titration: every 2 weeks (starting dose to maintenance)
- Route: oral
Claim dependency structure
- Independent: Claim 1
- Time dependent: Claims 2-3 (and then dose bands in 10-15)
- Dose dependent: Claims 4-9 (directly from Claim 1) and repeated for Claims 10-15 (from Claim 3)
- Titration dependent: Claims 16-25 (from Claim 1 via Claim 16)
- Route dependent: Claim 26 (from Claim 1)
Overlapping bands
The dose architecture is designed to leave fewer “holes”:
- Broad coverage (e.g., 25-500 mg, 500-2000 mg, 100-500 mg, 200-300 mg)
- Narrower coverage that still sits inside broader ranges (e.g., 300-500 mg inside 25-500 mg and inside maintenance brackets)
How does the patent read on real-world prescribing and product usage?
Regimen categories that can hit Claim 1
An accused regimen is most exposed when it satisfies:
- PWS diagnosis
- Once-daily diazoxide choline
- Clinical reduction of hyperphagia and one or more food-related behaviors
Because the endpoint is included in the claim language, infringement analysis typically turns on how the therapy is expected to behave and how it is evidenced clinically (labeling, trial protocols, clinician practice). Where the claim is framed as “method of treating,” proof often hinges on administration plus a reduction effect shown in practice or trials.
Regimen categories that can also trigger dependent claims
- 10+ weeks treatment: Claim 2
- 1+ year treatment: Claim 3 + the repeated mg bands (10-15)
- Dose inside any dependent mg band: claims 4-9 or 10-15
- Two-week titration cycle from a claimed starting dose to a claimed maintenance dose: claims 16-25
- Oral route: Claim 26
What is the patent’s likely competitive leverage?
Enforcement leverage comes from combining constraints
The combination of:
- a specific syndrome (PWS),
- a specific symptom construct (hyperphagia + food behaviors),
- once-daily dosing,
- diazoxide choline identity,
- oral administration,
- and titration timing (every two weeks)
creates a “pattern” that is harder to avoid than a pure composition claim.
Weak spots are mainly administrative
The only obvious “escape hatch” in the dependent claim set is route (Claim 26), and arguably the titration interval (Claims 16-25). But for standard clinical adoption, once-daily oral dosing with structured titration is typical, so these escape routes may narrow in practice rather than in theory.
What does the patent landscape imply for design-arounds?
Dose selection is not a strong design-around lever
Because the claims cover many overlapping bands, adjusting the dose to evade one range risks landing inside another.
Example of overlap logic (non-exhaustive):
- 60 mg/day fits within 25-100 mg (Claim 4) and within 50-180 mg (Claim 5)
- 240 mg/day fits within 50-275 mg (Claim 6) and within maintenance ranges like 200-300 mg (Claim 20) if using the titration path
Titration timing is a more targeted lever
Claim 16 locks titration to every two weeks. Changing titration cadence could, in principle, avoid Claims 16-25, but it does not avoid Claim 1 unless the regimen also fails the endpoint and once-daily PWS treatment elements.
Route changes can avoid Claim 26 only
Switching away from oral administration avoids the oral-specific limitation, but does not eliminate Claim 1 unless the rest of the accused regimen is also outside claim scope.
How to interpret claim strength for freedom-to-operate
Most valuable claim is Claim 1
Claim 1 is broad in two major ways:
- It covers any “effective amount” so long as the patient is treated once daily and reduction of hyperphagia and food behaviors occurs.
- It is not restricted to duration, dose band, titration schedule, or route.
The dependent claims add specificity and give additional enforcement points if the accused regimen matches the tighter constraints.
Dependent claims create multiple “assertable hooks”
If an accused product is used chronically and follows a structured titration, it can be mapped to several dependent claims simultaneously:
- duration (10+ weeks and/or 1+ year),
- dose band match,
- titration interval match,
- oral route match.
Key Takeaways
- US 12,419,895 claims a PWS hyperphagia treatment method using once-daily diazoxide choline with an outcome requirement: reduction of hyperphagia and one or more food-related behaviors.
- Claim 1 is the main breadth driver: it is not limited to dose band, treatment length, titration cadence, or oral route.
- Dependent claims add multiple enforcement “hooks” tied to (i) treatment duration (10+ weeks; 1+ year), (ii) many overlapping mg/day ranges, (iii) two-week titration cadence, and (iv) oral administration.
- Design-around by dose is weak because the patent uses overlapping quantitative ranges that leave few gaps.
- Design-around by titration schedule (not every two weeks) and/or route (not oral) offers more plausible separation, but does not neutralize exposure under Claim 1 if the overall regimen still matches the core treatment pattern.
FAQs
-
Does the patent cover diazoxide choline compositions or only methods?
It claims a method of treating PWS hyperphagia via once-daily administration of a diazoxide choline pharmaceutical formulation.
-
Is treatment duration required to infringe the patent?
Claim 1 does not require a specific duration. Claims 2 and 3 add duration limits (10+ weeks; 1+ year) and then attach additional dose-band coverage.
-
Do the dosing ranges overlap?
Yes. Several dependent claims cover overlapping mg/day intervals, which reduces the effectiveness of dose-only adjustments.
-
Is titration schedule part of the claim set?
Yes. Claims 16-25 require titration every two weeks from a starting dose to a maintenance dose in defined ranges.
-
Is oral administration required?
Claim 26 requires oral administration, but Claim 1 itself does not specify route. Oral therapy therefore heightens risk by satisfying additional dependent limitations.
References
[1] Patent claims provided in the prompt for US Drug Patent 12,419,895 (diazoxide choline; PWS hyperphagia; once-daily dosing; dependent limitations on duration, dose ranges, titration every two weeks, and oral route).
